Charles River, Valo Health create AI drug software

By The Science Advisory Board staff writers

April 28, 2022 -- Charles River Laboratories and Valo Health have launched Logica, an artificial intelligence (AI) powered drug discovery software application that creates a computation-powered, unified target-to-candidate offering.

Logica uses Valo's Opal computational platform and Charles River's preclinical expertise to provide advanceable leads and drug candidates with the goal of helping companies scale faster and make better drugs for their patients. The combined approaches have a demonstrated ability to produce an advanceable lead series 90% of the time and deliver development candidates 58% of the time, according to the firms.

Embedded in Logica are the exclusively available Logica Advanceable Lead (Logica-AL) and Candidate (Logica-C). Logica-AL provides information such as in vitro absorption, distribution, metabolism, and excretion, as well as selectivity profiles.

Logica-C uses the advanceable leads and trained predictive models to progress the program with the goal of delivering a development candidate that has undergone safety and efficacy tests and is ready for investigational new drug studies.

The software stems from a multiyear strategic partnership that Charles River and Valo announced in January.

Charles River acquires Explora BioLabs
Charles River Laboratories has acquired San Diego-based Explora BioLabs, a provider of contract vivarium research services.
Charles River expands strategic partnership with SAMDI Tech
Charles River Laboratories has expanded its strategic partnership with SAMDI Tech. The expanded agreement will provide Charles River's clients seamless...
Charles River, Valo Health announce strategic partnership
Charles River Laboratories and Valo Health have formed a multiyear strategic partnership to offer a transformative, artificial intelligence-enabled drug...
Valo Health, Khosla Ventures Acquisition to merge
Valo Health and Khosla Ventures Acquisition plan to merge to form a publicly traded company with an estimated pro forma market value of approximately...
Valo acquires PeptiBAC vaccine tech
Valo Therapeutics has acquired the intellectual property rights to the University of Helsinki's PeptiBAC cancer and infectious disease vaccination technology.

Copyright © 2022

Last Updated 4/28/2022 6:25:47 AM